Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Augmentation of ECT for Severe Major Depression
NCT01260649Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Ketamine + ECT with Placebo + ECT (2 arms). Primary endpoint: Change in Hamilton Depression Rating Scale - 28 at 1 month. Started Nov 2010; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01260649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01260649.